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Data-Driven Approaches for Drug Repurposing 
Due to advances in next generation sequencing (NGS) technologies and 
corresponding reductions in cost, it is now attainable to investigate 
genome-wide gene expression and variants at a patient-level, so as to 
better understand and anticipate heterogeneous responses to therapy. 
Consequently, it is feasible to design personalized drug treatment based 
on personal genomics data. However, there is a lack of reliable 
computational approaches for predicting effective drugs for individual 
patients. In our lab, we are developing data-driven computational 
approaches, and an open-source, visual programming computational 
platform to facilitate the fast development of drug repositioning 
approaches integrating personal genomics data with public available big 
data of pharmacogenomics.  
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Method Overview of MD-Miner for drug repurposing.  
MoAnet of Auranofil instance on 
A549 cell line. There are 121 genes 
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MoAnet of Auranofil instance.  
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Drug target and melanoma disease signaling network for vemurafenib 
+ vorinostat drug combination predicted by SynGeNet. Nodes 
highlighted in red and green represent gene targets of the first and 
second drug of the combination, respectively. Cyan nodes represent 
drug target genes shared by both drugs paired in the combination.  
MD-Miner: an open source, visual programming computational platform (no such 
platform exists specifically designed for personalized drug discovery) to enable the 
following: 1) help collect, clean, format and integrate diverse data sets (time-
consuming and nontrivial); 2) provide completed computational pipelines for 
predicting personalized drugs (germane to teaching and training new team 
members); 3) make methods development easy, fun and fast (even for those who are 
not computer-savvy) by visual programming to build a pipeline, similar to assembling 
LEGO toys. It is designed to help both clinical and bioinformatics researchers to 
develop and discover personalized precision medicine in a fast manner. 
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